TY - JOUR
T1 - The magnitude of reverse remodelling irrespective of aetiology predicts outcome of heart failure patients treated with cardiac resynchronization therapy
AU - Di Biase, Luigi
AU - Auricchio, Angelo
AU - Sorgente, Antonio
AU - Civello, Kenneth
AU - Klersy, Catherine
AU - Faletra, Francesco
AU - Riedlbauchova, Lucie
AU - Patel, Dimpi
AU - Arruda, Mauricio
AU - Schweikert, Robert A.
AU - Martin, David O.
AU - Saliba, Walid I.
AU - Moccetti, Tiziano
AU - Wilkoff, Bruce L.
AU - Natale, Andrea
N1 - Funding Information:
Dr Luigi Di Biase is a Research Fellow supported by a grant from the Italian Society of Cardiology (SIC).
Funding Information:
Conflict of interest: Dr Natale received research grants from St. Jude Medical and honoraria from Medtronic, Boston Scientific, St. Jude Medical Center, Stereotaxis, Biosense Webster and has served as a consultant and/or advisory board member for St. Jude Medical, Stereotaxis and Biosense Webster. Angelo Auric-chio is consultant to Boston Scientific, Medtronic, Sorin, Biotronik. His institution has received research grants from Boston Scientific and Medtronic. Antonio Sorgente is a research fellow at Fonda-zione Cardiocentro Ticino sponsored by Medtronic, Switzerland. Cristina Conca is a research fellow at Fondazione Cardiocentro Ticino sponsored by Boston Scientific, Switzerland. Catherine Klersy is statistical consultant to Boston Scientific and Medtronic. Bruce Wilkoff have received research grants from Medtronic, Boston Scientific, and St. Jude Medical Center, as well as honoraria from Medtronic, Boston Scientific, St. Jude Medical Center, and Stereotaxis and has served as a consultant and/or advisory board member for Medtronic, Boston Scientific, St. Jude Medical Center, and Stereotaxis. All the other authors have no special financial or other relations and interest conflicts to be disclosed.
PY - 2008/10
Y1 - 2008/10
N2 - Aims: We assessed the relationship between cardiac resynchronization therapy (CRT)-induced reverse remodelling and mortality during a long-term follow-up in a prospective observational study. Methods and results: We analyzed data from a prospective registry including 398 consecutive patients who underwent CRT between September 1998 and September 2007. Left ventricular ejection fraction (LVEF) was assessed before CRT and in the period between 3 and 6 months following implant. All-cause mortality, urgent transplantation and implantation of left ventricular assist device were all considered relevant events. A total of 398 (179 non-ischaemic and 219 ischaemic) patients were analysed. Overall, the increase of LVEF was statistically significant and was computed with 7.0 points (95% CI 5.8-8.3, P < 0.001). Non-ischaemic patients had a larger increase [9.2 points (95% CI 7.0-11.1), P < 0.001] of their LVEF from baseline, when compared with the ischaemic group. The median duration of follow-up was 4.4 years. The cumulative incidence of all events at the end of the 96 months period of follow-up was 55% and it was 34% (95% CI 29-40) at 5 years. At the multivariable analysis of the event-free survival, aetiology lost its predictive value (HR 0.92, P = 0.47), while a change in LVEF ≥6 points still significantly decreased the risk of event during the follow-up (HR 0.30, P = 0.001). Conclusion: Reverse remodelling measured by LVEF after 3 months is a good predictor of long-term outcome. Patients with an increase in LVEF ≥6 points have an excellent event-free survival approaching 66% at 5 years of follow-up.
AB - Aims: We assessed the relationship between cardiac resynchronization therapy (CRT)-induced reverse remodelling and mortality during a long-term follow-up in a prospective observational study. Methods and results: We analyzed data from a prospective registry including 398 consecutive patients who underwent CRT between September 1998 and September 2007. Left ventricular ejection fraction (LVEF) was assessed before CRT and in the period between 3 and 6 months following implant. All-cause mortality, urgent transplantation and implantation of left ventricular assist device were all considered relevant events. A total of 398 (179 non-ischaemic and 219 ischaemic) patients were analysed. Overall, the increase of LVEF was statistically significant and was computed with 7.0 points (95% CI 5.8-8.3, P < 0.001). Non-ischaemic patients had a larger increase [9.2 points (95% CI 7.0-11.1), P < 0.001] of their LVEF from baseline, when compared with the ischaemic group. The median duration of follow-up was 4.4 years. The cumulative incidence of all events at the end of the 96 months period of follow-up was 55% and it was 34% (95% CI 29-40) at 5 years. At the multivariable analysis of the event-free survival, aetiology lost its predictive value (HR 0.92, P = 0.47), while a change in LVEF ≥6 points still significantly decreased the risk of event during the follow-up (HR 0.30, P = 0.001). Conclusion: Reverse remodelling measured by LVEF after 3 months is a good predictor of long-term outcome. Patients with an increase in LVEF ≥6 points have an excellent event-free survival approaching 66% at 5 years of follow-up.
KW - Cardiac resynchronization therapy
KW - Ejection fraction
KW - Heart failure
KW - Ischaemic and non-ischaemic aetiology
UR - http://www.scopus.com/inward/record.url?scp=54149092991&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=54149092991&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/ehn221
DO - 10.1093/eurheartj/ehn221
M3 - Article
C2 - 18515806
AN - SCOPUS:54149092991
SN - 0195-668X
VL - 29
SP - 2497
EP - 2505
JO - European Heart Journal
JF - European Heart Journal
IS - 20
ER -